Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

  • Post author:
  • Post category:uncategorized

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens…

Continue ReadingNeoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma